

9/889344
JG18 Rec'd PCT/PTO 16 JUL 2001

"EXPRESS MAIL CERTIFICATE"
"EXPRESS MAIL" MAILING LABEL NUMBER EL 300 526 894 US
DATE OF DEPOSIT 16 July 2001

Attorney Docket No. P50892

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US00/01481	20 January 2000	22 January 1999


TITLE OF INVENTION
METHOD OF SITE SPECIFIC LABELING OF PROTEINS AND USES THEREFOR

APPLICANT(S) FOR DO/US
Wenfang CHEN, Thomas D. MEEK, David J. POWELL, and David G. TEW

FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed, except for those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,


Edward R. Gimmi
Attorney for Applicants
Registration No. 38,891

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090
N:\ERG\APPS\P50892\usnatl\IDS\ltr.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50892	INTERNATIONAL APPLICATION NUMBER PCT/US00/01481
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANTS Wenfang Chen, <i>et al.</i>	
		INTERNATIONAL APPLICATION DATE 20 January 2000	GROUP Unknown

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AA	EP 0725145	07.08.96	EPO				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AB	Sato, <i>et al.</i> , "Site-Specific Modification of Interleukin-2 by the Combined Use of Genetic Engineering Techniques and Transglutaminase," <i>Biochemistry</i> , 35: 13072-13080 (1996).
AC	Gorman, <i>et al.</i> , "Structural features of Glutamine substrates for transglutaminases," <i>Journal of Biological Chemistry</i> , 259(14): 9007-9010 (1984).
AD	Gorman, <i>et al.</i> , "Structural features of Glutamine substrates for transglutaminases," <i>Journal of Biological Chemistry</i> , 256(6): 2712-2715 (1981).
AE	Gorman, <i>et al.</i> , "Structural features of Glutamine substrates for human plasma Factor XIIIa," <i>Journal of Biological Chemistry</i> , 255(2): 419-427 (1980).
AF	Lorand, <i>et al.</i> , "New colored and fluorescent anime substrates for activated fibrin stabilizing factor (Factor XIIIa) and for transglutaminase," <i>Analytical Biochemistry</i> , 131(2): 419-425 (1983).
AG	Perez-Paya, <i>et al.</i> , "Selective labelling of melittin with a fluorescent dansylcadaverine probe using guinea-pig liver transglutaminase," <i>FEBS Letters</i> , 278(1): 51-54 (1991).
AH	Slaughter, <i>et al.</i> , "A microtiter plate transglutaminase assay utilizing 5-(biotinamido) pentylamine as substrate," <i>Analytical Biochemistry</i> , 205(1): 166-171 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.